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httpCurrent efﬁcacy of open and endovascular
interventions for advanced superﬁcial femoral artery
occlusive disease
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Mitul S. Patel, MD, Hosam F. El-Sayed, MD, Alan B. Lumsden, MD, andMark G. Davies, MD, PhD, MBA,
Houston, Tex
Background: There has been a marked paradigm shift in the treatment of symptomatic femoro-popliteal disease with
a shift from open to endoluminal therapy. The consequence of this shift in therapy is poorly described. The aim of this
study is to examine the clinical efﬁcacy of this shift in treatment strategies.
Methods: A database of patients undergoing open (OPEN) and endoluminal (ENDO) intervention for TASC II C and D
femoro-popliteal lesions between 1990 and 2010 was retrospectively queried. Kaplan-Meier survival analyses were per-
formed to assess time-dependent outcomes. Factor analyses were performed using a multivariant Cox proportional hazard
model for time-dependent variables.
Results: A total of 2593 limbs underwent either OPEN or ENDO treatment for symptomatic and anatomically advanced
femoro-popliteal disease over a 20-year period. There was a two-fold rise in endovascular interventions between the ﬁrst
and second decade. In the ﬁrst decade, 80% of the interventions were OPEN, while in the second decade, 61% of the
interventions were ENDO. There were equivalent comorbidities in both groups, and survival was also equivalent.
Endoluminal therapy was more commonly performed on claudicants. Thirty-day mortality was equivalent, but major
morbidity was higher in OPEN compared with ENDO. Cumulative patency was equivalent in both groups with a similar
reintervention rate. In contrast, clinical efﬁcacy (freedom from recurrent symptoms, maintenance of ambulation, and
avoidance of major amputation) was signiﬁcantly higher in the OPEN group (P [ .002). The presence of critical limb
ischemia, diabetes, end-stage renal disease, and poor tibial runoff were predictors of poor anatomic and functional
outcomes in both groups.
Conclusions: There has been a marked shift in treatment modality for advanced femoro-popliteal disease with a lowering of
the symptomatic threshold for intervention over 2 decades, likely spurred by the ease of endoluminal interventions.
Although peri-procedural and anatomic outcomes for both procedures are equivalent, it appears that open surgery carries
a superior long-term clinical efﬁcacy. This superiority is negatively inﬂuenced by poor preoperative ambulation status, high
modiﬁedCardiacRisk Score, worse presenting symptoms, the occurrence ofmajor adverse cardiovascular events, poor tibial
runoff, the absence of hemodynamic success, and occlusion of the original bypass. (J Vasc Surg 2013;58:1267-75.)Over half of all peripheral vascular disease involves the
superﬁcial femoral artery (SFA).1 The ﬁrst endovascular
SFA interventions were reported over 40 years ago.2
However, the past 20 to 30 years have seen the most rapid
growth and change in this treatment ﬁeld.3 It is during
this time that a paradigm shift in the treatment of symptom-
atic femoro-popliteal disease from open to endoluminal
therapy has occurred.4,5 Reports have suggested differencesthe Department of Cardiovascular Surgery, Houston Methodist
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treatment modalities.6 Objective performance goals have
been sought and described for evaluating catheter-based
treatment vs traditional surgical bypass in the treatment of
critical limb ischemia.7 However, the consequences of
endovascular therapy are still evolving and still described
via inconsistent reporting metrics.8 We have previously
demonstrated the impact of various factors on SFA interven-
tions as well as the disparities in anatomic outcomes and
objective performance goals in patients undergoing lower
extremity endovascular interventions vs open bypasses.9-11
This report examines the anatomic and clinical efﬁcacy of
this shift in treatment strategies over two decades of practice
and the factors that drive functional outcomes.
METHODS
Study design. A database of patients undergoing
treatment of lower extremity arterial disease between
1990 and 2010 was retrospectively queried. The group
receiving treatment of the SFA were identiﬁed and further
stratiﬁed into those undergoing surgical revascularization
and those receiving endoluminal therapy. Data utilization1267
Table I. Characteristics of patients
ENDO OPEN P value
Demographics
Limbs treated, No. 1177 1416
Male 64 58 .05a
Average age, years 67 6 13 67 6 14 1.00b
Symptoms
Claudication 53 50 .0001c
Rest pain 20 28
Tissue loss 28 22
Comorbidities
Cardiac risk index 3.4 6 1.8 3.0 6 1.6 .0001b
Smoking history 73 83 .0001b
Current smoker 20 13 .0001b
Coronary artery disease 62 66 .035b
Congestive heart failure 29 26 .093b
Hypertension 91 72 .0001b
Diabetes 54 42 .0001b
Hyperlipidemia 67 44 .0001b
Statin 63 33 .0001b
Metabolic syndrome 44 29 .0001b
Chronic kidney disease 28 25 .081b
On hemodialysis 10 8 .072b
Transient ischemic attack/
cerebrovascular accident
13 6 .0001b
Carotid endarterectomy 12 11 .46b
Hypothyroidism 12 7 .001b
Hypercoagulability 4 6 .025b
Preoperative ambulatory status
Ambulatory 54 61 .0001c
Ambulatory/homebound 40 38
Nonambulatory/transfer 4 1
Nonambulatory/bedridden 2 0
ENDO, Endoluminal intervention; OPEN, open intervention.
Data are presented as percentages or mean ± standard deviations.
aMann Whitney test.
bFisher exact test.
cc2 test.
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as deﬁned by the Institutional Review Board and Health
Insurance Portability and Accountability Act.
Study setting. Academic Medical Center with 1000
beds in a catchment area of 5 million people. It is a tertiary
and quaternary referral facility.
Methodology. For each patient captured, demo-
graphics, symptoms, existing comorbid conditions, and
risk factors for atherosclerosis were identiﬁed. Therapy for
individual patients was dictated by individual attending
physician preference and was not regulated by unit guide-
lines. All patients received aspirin daily (81 mg or 325
mg) as a general cardiovascular protection agent. In the
past 5 years, all patients received statins and beta-blockers
in addition to aspirin for cardiovascular protection if no
contraindications.
Noninvasive studies were performed initially on all
patients receiving a work-up for peripheral arterial disease.
Seventy-three percent of the OPEN group and 88% of the
ENDO group had a duplex at last follow-up. Mean follow-
up was 6.13 years (range, 0-19.4 years) and 4.56 years
(range, 0-19.6 years) for the OPEN and ENDO groups,
respectively. Patients with serious symptoms or signs of
severe stenosis/occlusion based upon the initial noninva-
sive tests received angiograms. Angiograms and angio-
graphic reports were reviewed; lesions were described by
length, calciﬁcation, and patency and then categorized
under the TransAtlantic Inter-Society Consensus II
(TASC II) system.12 Of note, those angiograms performed
prior to TASC II publication were rescored according to
TASC II criteria for consistency. The preoperative distal
runoff was scored by the number of patent tibial vessels
and according to a modiﬁcation of Society for Vascular
Surgery (SVS) criteria employed for determining bypass
runoff (using the cumulative score for the distal popliteal
from knee joint to ﬁrst tibial branch; maximum 9þ1) and
each of the tibial vessels to the ankle (maximum 3 each),
giving a maximum possible total score of 19.13,14 This
modiﬁcation has been previously published by our group.14
Angioplasty was performed with a patient under
systemic heparin administration (40-60 Units/kg), and
completion angiography was performed to assess the tech-
nical result. Stents were utilized (at the discretion of the
operator) primarily or as an adjunct for ﬂow-limiting
dissections, intimal ﬂaps, or poor technical results ($50%
residual stenosis).
Patients underwent routine duplex ultrasound follow-
up at 1, 3, and every 6 months following their procedure
using criteria previously described by our group.14 During
follow-up, angiography was only performed if noninvasive
studies suggested restenosis/occlusion (positive duplex
scan with a drop in ankle-brachial index [ABI] of >0.15
and toe-brachial index of >0.1), and the patient had recur-
rent symptoms.
Statistical analysis. All statistical analyses were per-
formed on an “intention-to-treat” basis. Measured values
are reported as percentages or means 6 standard deviation
(SD). Patency and limb salvage rates were calculated usingKaplan-Meier analyses and reported using current SVS
criteria and objective performance goals.7,13 Standard
errors are reported in Kaplan-Meier analyses. Deﬁnitions of
all outcome parameters used are shown in the appendix.
The log rank test was used to determine differences
between life tables. Nonparametric testing or c2 were used
to analyses individual variables. Univariant and multivariant
Cox regression analyses were performed for independent
variables. Analyses were performed using JMP software,
version 9.0 (SAS Institute, Cary, NC).
RESULTS
Patient population. A total of 2593 limbs underwent
either surgical revascularization (OPEN cohort) or endo-
vascular treatment (ENDO cohort) for symptomatic and
anatomically advanced femoro-popliteal disease over the
20-year period. In the ﬁrst decade studied, 80% of all
procedures performed were OPEN, while in the second
decade, 61% of all procedures were ENDO. In total, 1177
limbs underwent ENDO treatment, and 64% of these
interventions were in males, while in the OPEN group,
58% of the interventions were in males (P ¼ .05; Table I).
One thousand four hundred sixteen limbs underwent
Table II. Runoff and lesion characteristics
ENDO OPEN P value
Tibial runoff
Tibial vessels, No. 2.0 6 0.8 1.9 6 0.8 .003a
Modiﬁed SVS
runoff score
5.7 6 3.4 6.8 6 4.5 .0001a
TASC II category
C 61 4 .0001b
D 39 96
Amputation risk score ENDO OPEN P value
PREVENT III 2.4 6 2.3 2.1 6 1.9 .0004a
Low (0-3) 73 78 .0005b
Medium (4-7) 22 20
High (>7) 5 1
ENDO, Endoluminal intervention; OPEN, open intervention; PREVENT
III, Project of Ex-vivo Vein Graft Engineering via Transfection III; SVS,
Society for Vascular Surgery; TASC II, TransAtlantic Inter-Society
Consensus II.
Data are presented as percentages or mean 6 standard deviations.
aMann Whitney test.
bFisher exact test.
Table III. Mortality, morbidity, and objective
performance goals
ENDO, % OPEN, % P value
Mortality and morbidity
Mortality 1.5 2 .456a
Morbidity 3 8 .001a
Reintervention rate 27 22 .004a
OPG
30-day MACE 3 7 .001a
30-day MALE 11 5 .001a
30-day major amputations 4 2 .001a
ENDO, Endoluminal intervention; MACE, major adverse cardiovascular
event; MALE, major adverse limb event; OPEN, open intervention; OPG,
objective performance goals.
aFisher exact test.
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bypass. Fifty-six percent were bypasses to the above-knee
popliteal artery; 44% were to the below-knee popliteal
artery. Sixty-nine percent of the bypasses were performed
with prosthetic graft, while the remainder (31%) utilized
vein conduit. Fifty-three percent of the revascularizations
were for lifestyle-limiting claudication in the OPEN group
and, similarly, 50% of the interventions were performed for
this reason in the ENDO group. The remainder in each
group was for treatment of rest pain and/or tissue loss, and
there was no signiﬁcant difference between OPEN and
ENDO in either category. When the Project of Ex-vivo
Vein Graft Engineering via Transfection III (PREVENT
III) risk of amputation score is applied, the distribution of
the low-, medium-, and high-risk groups was signiﬁcant
with the open group having lower risk amputation patients
(Table II). Age was similar in both groups. Past smoking
history and current smoking signiﬁcantly different between
the groups, though each in an opposing distribution
(Table I). Initial ABI between groups was similar (0.49 6
0.17 vs 0.53 6 0.15; OPEN vs ENDO; P ¼ 1.0). Existing
disease at other levels, aorto-iliac or tibial disease, was
treated concomitantly during the same admission and was
equivalent between groups (18% vs 16%; OPEN vs ENDO;
P ¼ .9). There were not a signiﬁcantly higher number of
patients in either group with the following comorbidities:
coronary artery disease, congestive heart failure, chronic
kidney disease with or without dialysis, and hypercoagula-
bility (Table I). However, there was a signiﬁcant difference
between the groups regarding hypertension, diabetes,
hyperlipidemia, metabolic syndrome, cerebrovascular
disease, transient ischemic attack/cerebrovascular accident,
and hypothyroidism (Table I). Preoperative ambulatory
status did not differ between groups (Table I). All patients
treated in this study had either TASC II C or D lesions.
Patients receiving OPEN therapy had a signiﬁcantly higher
percentage of patients with number of TASC II D lesions
(Table II). Metrics used to grade the runoff showed
a difference in the number of tibial runoff vessels between
the groups as well as a difference in modiﬁed SVS runoff
score, higher in the OPEN group (Table II).
Immediate outcomes. The technical failure rates
(failed, incomplete, or suboptimal revascularization) were
4% for patients treated with ENDO. Eventual need for
open bypass surgery in the ENDO group in the following
3 months was 14%. These bypasses were done for
thrombosed or failed endovascular intervention. Thirty-
day mortality was similar in the groups. Peri-operative
morbidity, consisting of MI, stroke, reintervention on
same leg, access site complications, and wound complica-
tions, was higher in the OPEN group (Table III).
Thirty-day major adverse cardiac events (MACE), deﬁned
as MI, stroke, or death, were higher in the OPEN group.
Thirty-day major adverse limb events (MALE), deﬁned as
amputation or endovascular or open re-intervention on
same leg, were higher in the ENDO group (Table III).
Hemodynamically, there was an increase in ABIs in both
groups, with >75% of all treated patients having an ABIincrease >0.15, no difference between groups. However,
the mean change in ABI was signiﬁcantly greater in the
OPEN group (Table IV). Following intervention, a similar
percentage of patients in each group achieved immediate
symptom relief. Postoperative ambulatory status was also
similar between the ENDO and OPEN groups. Status at
discharge did differ between the groups, with a larger
percentage of ENDO patients transferring to rehabilitation
facilities (Table IV).
Long-term anatomic outcomes. There was a small
but signiﬁcant difference in the primary patency, as deﬁned
by SVS reporting standards, between groups at 5 years
(P ¼ .04), but there was no difference in assisted primary
patency, as deﬁned by SVS reporting standards (Fig 1, A
and B). There was also no difference in secondary/cumu-
lative patency, as deﬁned by SVS reporting standards, at
5 years (Fig 1, C). Overall, the number of major amputa-
tions (below- or above-the-knee) was similar between
Table IV. Hemodynamic changes and immediate
symptom relief
ENDO OPEN P value
Hemodynamic changes
Change in ABI 0.3 6 0.31 0.56 6 0.23 .0001a
ABI increase >0.15 79 76 .073b
Immediate symptom relief
Resolved 41 53 .001c
Improved 42 38
No change 16 8
Deterioration 1 1
Postoperative ambulatory status
Ambulatory 78 81 .0001c
Ambulatory/homebound 9 17
Nonambulatory/transfer 6 6
Nonambulatory/bedridden 7 6
Discharge status
Home 73 79 .0001c
Rehabilitation facility 17 11
Skilled nursing facility 9 8
Hospital 1 2
ABI, Ankle-brachial index; ENDO, endoluminal intervention; OPEN, open
intervention; SD, standard deviation.
Data are presented as percentages or mean 6 standard deviations.
aMann Whitney test.
bFisher exact test.
cc2 test.
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knee amputations in the ENDO group (Table V).
Long-term functional outcomes. Limb salvage was
greater in the OPEN group at 5 years (P ¼ .02;
Fig 2, A). There was no difference between the groups
regarding amputation-free survival, or patient survival plus
limb salvage, at 5 years (Fig 2, B). MALE, deﬁned as above,
at 5 years was signiﬁcantly higher in the ENDO group
(P ¼ .01; Fig 2, C). Clinical efﬁcacy, deﬁned as absence of
recurrent symptoms, maintenance of ambulation, and limb
preservation, at 5 years was signiﬁcantly higher in the
OPEN group (P ¼ .02; Fig 2, D). Overall mortality was
greater in the OPEN group at 5 years (P ¼ .04; Fig 2, E).
A Cox regression multivariant analysis was performed
to examine factors that inﬂuenced the long term outcomes
in both ENDO and OPEN groups.
ENDO group. The patient factors of creatinine >2
mg/dL, on hemodialysis, and the presence of diabetes,
poor tibial runoff, and the absence of hemodynamic success
had a negative inﬂuence on primary patency, assisted primary
patency, and secondary patency (Table VI). Shorter survival
was inﬂuenced by a high modiﬁed Cardiac Risk Score,
presence of diabetes, presence of hemodialysis, worse pre-
senting symptoms, and a MACE. Limb salvage was
inﬂuenced negatively by presence of diabetes, creatinine >2
mg/dL, on hemodialysis, poor tibial runoff, the absence of
hemodynamic success, and occlusion of the original site of
intervention (Table VI). Clinical efﬁcacy and amputation-
free survival were effected by poor preoperative ambula-
tion status, high modiﬁed Cardiac Risk Score, presence
of diabetes, presence of hemodialysis, worse presentingsymptoms, a MACE, poor tibial runoff, the absence of
hemodynamic success, and occlusion of the original site of
intervention (Table VI). Freedom fromMALE was reduced
by presence of diabetes, presence of hemodialysis, worse
presenting symptoms, poor tibial runoff, and the absence of
hemodynamic success (Table VI).
OPEN group. In the OPEN group, the presence of
creatinine >2 mg/dL, and presence of diabetes, poor tibial
runoff, use of prosthetic, and the absence of hemodynamic
success had a negative inﬂuence on primary patency, assis-
ted primary patency, secondary patency, survival, limb
salvage, amputation-free survival, MALE, and clinical efﬁ-
cacy (Table VI). Worse presenting symptoms did not inﬂu-
ence outcomes, and the presence of hemodialysis only
inﬂuenced assisted primary patency. Lower survival was
inﬂuenced by a high modiﬁed Cardiac Risk Score, presence
of diabetes, presence of hemodialysis, worse presenting
symptoms, and aMACE (Table VI). Decreased limb salvage
was found in the presence of diabetes, on hemodialysis,
worse presenting symptoms, poor tibial runoff, the absence
of hemodynamic success, and occlusion of the original
bypass (Table VI). Clinical efﬁcacy and amputation-free
survival, deﬁned as any above-ankle amputation of the
index limb or death (any cause), perioperative death, or any
major adverse limb event (MALE), were effected by poor
preoperative ambulation status, high modiﬁed Cardiac Risk
Score, worse presenting symptoms, a MACE, poor tibial
runoff, the absence of hemodynamic success, and occlusion
of the original bypass (Table VI). The presence of diabetes
decreased clinical efﬁcacy while the presence of hemodialysis
decreased amputation-free survival. Freedom from MALE
was reduced by presence of diabetes, worse presenting
symptoms, poor tibial runoff, and the use of prosthetic
material (Table VI).
DISCUSSION
In this study, we analyzed the short- and long-term
outcomes between groups of patients undergoing either
SFA endovascular intervention or surgical revascularization
for symptomatic disease in TASC II C and D lesions.
The key differences between the groups in the 30 days
postprocedure were MALE and 30-day major amputa-
tions, which were higher in the ENDO group, and
all-cause morbidity and MACE, which were higher in
the OPEN group. Immediate postprocedural hemody-
namic/symptom improvement and restoration of impaired
ambulation were equivalent in both groups over time.
However, the long-term differences between the groups
were mostly related to clinical efﬁcacy rather than anatomic
patency, with clinical efﬁcacy signiﬁcantly greater in the
OPEN group compared with the ENDO group. This
was despite the fact that the factors identiﬁed (poor preop-
erative ambulation status, high modiﬁed Cardiac Risk
Score, worse presenting symptoms, the occurrence of
MACE, poor tibial runoff, the absence of hemodynamic
success, and occlusion of the original site of intervention
or bypass) to contribute to poor outcomes were similar
in each group. This improvement in clinical efﬁcacy was
Fig 1. Anatomic outcomes. Kaplan-Meier analysis of patients with open (OPEN) or endovascular (ENDO) inter-
ventions. Data are the mean6 standard error of the mean and number of limbs at risk shown in the table. No error bars
are shown if the standard error of the mean is >10%, and the data set terminates if the number at risk is <10. Log rank
sum test was performed for statistical analysis. A, Primary patency. B, Assisted primary patency. C, Secondary patency.
Table V. Minor and major amputations
ENDO, % OPEN, % P value
Amputation
No amputation 81 78 .001a
Toe and/or forefoot 6 10
Major amputation 13 12
Below-knee amputation 31 50 .0001b
Above-knee amputation 69 50
ENDO, Endoluminal intervention; OPEN, open intervention.
ac2 test.
bFisher exact test.
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survival in the OPEN group, but rather by the deﬁned
elements of absence of recurrent symptoms, maintenance
of ambulation, and limb preservation. The factors we iden-
tiﬁed as important in this regard because of their negative
impact on the superiority of OPEN bypass were poor
preoperative ambulation status, high modiﬁed Cardiac
Risk Score at presentation, worse presenting symptoms atpresentation, the occurrence of MACE, poor tibial runoff,
the absence of hemodynamic success, and occlusion of the
original bypass. These are consistent with the literature.
Presentation. This study focused on advanced
TASC II lesions (C and D); however, compared with the
ENDO group, the OPEN group had a greater percentage
of D lesions. This would reﬂect the preference to treat
these advanced lesions open, which was the recommen-
dation of both TASC I and TASC II. We did not ﬁnd that
the patients in either group were more likely to present
with more advanced symptoms of rest pain or tissue loss as,
in this study, presenting symptoms were equivalent, sug-
gesting that there was no bias in this particular regard.
However, the PREVENT III risk of amputation was lower
in the OPEN group compared with the ENDO group.
This is also supported by the ﬁndings that the OPEN
group had better runoff as evidenced by the statistically
signiﬁcant number of patent tibial runoff vessels as well as
a lower modiﬁed SVS runoff score compared with the
ENDO group. This must be understood to reﬂect appro-
priate selection bias and may have inﬂuenced the
Fig 2. Functional outcomes: Kaplan-Meier analysis of patients with open (OPEN) or endovascular (ENDO) inter-
ventions. Data are the mean 6 standard error of the mean and number of patients or limbs at risk shown in the table.
No error bars are shown if the standard error of the mean is >10% and the data set terminates if the number at risk
is <10. Log rank sum test was performed for statistical analysis. A, Survival. B, Limb salvage. C, Amputation-free
survival. D, Freedom from MALE. E, Clinical efﬁcacy. MALE, Major adverse limb event.
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the literature, this study demonstrated that patients pre-
senting with worse symptoms in both ENDO and OPEN
had poorer short-term and long-term outcomes. We have
previously shown that the presence of metabolic syndrome,
diabetes alone, chronic kidney disease, and dialysis willnegatively affect outcomes after SFA intervention.9-11,15,16
The ENDO group has a greater percentage of patients with
diabetes and metabolic syndrome, which is a reﬂection of
the changes in demographics in the vascular population
over time, linked to the shift to more endovascular
procedures. Furthermore, several other authors have
Table VI. Multivariant proportional hazards analysis
ENDO
Patency Primary Assisted primary Secondary
Diabetes 0.68 (0.53-0.88); P ¼ .004 0.35 (0.25-0.66); P ¼ .003 0.42 (0.22-0.42); P ¼ .01
Creatinine >2 mg/dL 0.34 (0.32-0.67); P ¼ .01 0.44 (0.34,0.55); P ¼ .002 0.62 (0.43-0.84); P ¼ .02
Hemodialysis 0.32 (0.22-0.45); P ¼ .001 0.42 (0.26-0.65); P ¼ .001 0.77 (0.65-0.94); P ¼ .007
Worse pre-procedure symptom 0.42 (0.32-0.54); P ¼ .001 0.31 (0.29-0.56); P ¼ .001 0.31 (0.22-0.42); P ¼ .001
Poor tibial runoff 0.44 (0.22-0.87); P ¼ .01 0.32 (0.22-0.45); P ¼ .001 0.72 (0.53-0.94); P ¼ .02
No hemodynamic success 0.54 (0.43-0.69); P ¼ .001 0.88 (0.32-0.66); P ¼ .001 0.59 (0.46-0.87); P ¼ .001
Life and limb Survival Limb salvage
High modiﬁed cardiac risk score 0.52 (0.33-0.8); P ¼ .002
Diabetes 0.72 (0.52-0.99); P ¼ .04 0.52 (0.33-0.8); P ¼ .002
Creatinine >2 mg/dL 0.60 (0.39-0.92); P ¼ .023
Hemodialysis 0.30 (0.05-0.96); P ¼ .025 0.61 (0.23-0.97); P ¼ .04
Worse pre-procedure symptom 0.52 (0.41-0.66); P ¼ .001 0.29 (0.17-0.49); P ¼ .0001
Poor tibial runoff 0.67 (0.49-0.91); P ¼ .01
MACE 0.04 (0.08-0.02); P ¼ .001
No hemodynamic success 0.35 (0.16-0.72); P ¼ .034
Occlusion at site of intervention 0.31 (0.21-0.39); P ¼ .005
Patient-centered outcomes Clinical efﬁcacy Amputation-free survival Freedom from MALE
Poor preoperative ambulation status 0.34 (0.15-0.66); P ¼ .005 0.59 (0.43-0.75); P ¼ .02
High modiﬁed cardiac risk score 0.41 (0.23-0.68); P ¼ .007 0.86 (0.77-0.98); P ¼ .017
Diabetes 0.61 (0.49-0.77); P ¼ .006 0.55 (0.32-0.77); P ¼ .001 0.56 (0.41-0.78); P ¼ .004
Hemodialysis 0.32 (0.22-0.45); P ¼ .001 0.42 (0.26-0.65); P ¼ .001 0.77 (0.65-0.94); P ¼ .007
Worse pre-procedure symptom 0.76 (0.60-0.97); P ¼ .03 0.50 (0.38-0.67); P ¼ .001 0.53 (0.41-0.67); P ¼ .001
Poor tibial runoff 0.69 (0.56-1.67); P ¼ .03 0.77 (0.65-0.93); P ¼ .004 0.92 (0.75-1.15); P ¼ .044
MACE 0.49 (0.27-0.95); P ¼ .037 0.40 (0.18-0.82); P ¼ .02
No hemodynamic success 0.54 (0.43-0.69); P ¼ .001 0.67 (0.52-0.88); P ¼ .004 0.58 (0.44-0.88); P ¼ .019
Occlusion at site of intervention 0.62 (0.32-0.74); P ¼ .001 0.43 (0.32-0.65); P ¼ .005
OPEN
Patency Primary Assisted primary Secondary
Diabetes 0.77 (0.67-0.92); P ¼ .003 0.78 (0.65-0.95); P ¼ .012 0.78 (0.78-0.94); P ¼ .013
Creatinine >2 mg/dL 0.78 (0.78-0.99); P ¼ .046 0.74 (0.67-0.99); P ¼ .048 0.73 (0.55-0.98); P ¼ .032
Hemodialysis 0.64 (0.45-0.98); P ¼ .039
Worse pre-procedure symptom
Poor tibial runoff 0.73 (0.59-0.91); P ¼ .002 0.62 (0.48-0.78); P ¼ .005 0.69 (0.49-0.95); P ¼ .023
Use of prosthetic 0.64 (0.50-0.80); P ¼ .02 0.74 (0.60-0.90); P ¼ .002 0.73 (0.59-0.90); P ¼ .002
No hemodynamic success 0.81 (0.42-0.92); P ¼ .01 0.69 (0.45-0.86); P ¼ .012 0.57 (0.38-0.75); P ¼ .001
Life and limb Survival Limb salvage
High modiﬁed cardiac risk score 0.81 (0.70-0.94); P ¼ .006
Diabetes 0.82 (0.72-0.94); P ¼ .003 0.77 (0.67-0.88); P ¼ .004
Creatinine >2 mg/dL
Hemodialysis 0.57 (0.48-0.71); P ¼ .001 0.61 (0.46-0.82); P ¼ .001
Worse pre-procedure symptom 0.69 (0.61-0.80); P ¼ .001 0.75 (0.66-0.85); P ¼ .001
Poor tibial runoff 0.22 (0.09-0.72); P ¼ .001
MACE 0.41 (0.29-0.61); P ¼ .001
No hemodynamic success 0.88 (0.78-1.01); P ¼ .04
Bypass occlusion 0.85 (0.75-0.98); P ¼ .012
Patient-centered outcomes Clinical efﬁcacy Amputation-free survival Freedom from MALE
Poor preoperative ambulation status 0.34 (0.32-0.37); P ¼ .001 0.55 (0.44-0.61); P ¼ .001
High modiﬁed cardiac risk score 0.94 (0.90-0.99); P ¼ .0001 0.95 (0.92-0.99); P ¼ .02
Diabetes 0.74 (0.63-0.87); P ¼ .0002 0.77 (0.67-0.91); P ¼ .0014
Hemodialysis 0.65 (0.48-0.97); P ¼ .005
Worse pre-procedure symptom 0.76 (0.65-0.91); P ¼ .001 0.64 (0.56-0.74); P ¼ .03 0.74 (0.55-0.94); P ¼ .04
Poor tibial runoff 0.62 (0.51-0.77); P ¼ .001 0.74 (0.62-0.86); P ¼ .0002 0.70 (0.57-0.86); P ¼ .002
Use of prosthetic 0.86 (0.75-0.99); P ¼ .04 0.52 (0.01-0.29); P ¼ .007 0.56 (0.29-0.95); P ¼ .03
MACE 0.51 (0.34-0.81); P ¼ .006 0.62 (0.41-0.92); P ¼ .04
No hemodynamic success 0.46 (0.23-0.84); P ¼ .008 0.72 (0.51-0.90); P ¼ .02
Bypass occlusion 0.24 (0.21-0.28); P ¼ .001 0.71 (0.62-0.82); P ¼ .001
ENDO, Endoluminal intervention; MACE, major adverse cardiovascular event; MALE, major adverse limb event; OPEN, open intervention.
Values are risk ratio (95% conﬁdence intervals).
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1274 Smolock et al November 2013demonstrated that the severity of presenting symptoms,17
lesion severity,18,19 and poor tibial runoff will affect the
outcomes of SFA endovascular interventions.14
Anatomic outcomes. The 5-year primary patency was
greater in the OPEN group compared with the ENDO
group, which is consistent with previous reports.6,8 While
the study did have a large number of prosthetic bypasses,
reﬂecting the environment we work in, it is clear from the
analysis that vein bypasses performed better than prosthetic
bypasses. As a result of the greater number of prosthetic
bypasses, the secondary patency was similar between the
ENDO and OPEN groups with an equal number of rein-
terventions. Patency was dependent on the quality of tibial
runoff and was inﬂuenced by the presence of diabetes and
chronic renal insufﬁciency. Occlusion of the site of inter-
vention or occlusion of the bypass did affect functional
outcomes and the likelihood of amputation.
Functional outcomes. While anatomic outcomes have
been the focus of many reports in the literature, the unique
aspect of this report is the focus on functional outcomes.
Functional outcomes, namely reduction in symptoms, pres-
ervation of limb, and maintenance of ambulation, are the
ultimate goal of all vascular interventions. There has been
a decrease in major amputations reported in the Nation-
wide Inpatient Sample, associated with an increase in endo-
luminal interventions and a decrease in surgical procedures
over the past few decades for a variety of reasons.6 The
ENDO group in this study had a greater number of 30-day
major amputations as well as poorer long-term limb
salvage. This was driven by presence of diabetes, creatinine
>2 mg/dL, on hemodialysis, poor tibial runoff, the
absence of hemodynamic success, and occlusion of the
original site of intervention. The increased amputation rate
contributed to poor amputation-free survival and poor
clinical efﬁcacy. The most signiﬁcant ﬁnding in this study
is that the group receiving OPEN therapy had greater
long-term clinical efﬁcacy despite long-term cumulative
patency equal to that of ENDO. This occurred despite the
fact that there were an equivalent number of patients
showing an initial ABI/toe-brachial index rise >0.15 and
a majority of the patients showing initial improvement or
resolution of symptoms in both groups.
Study limitations. This study is retrospective in nature,
and the clinical decision-making was individualized, not
driven by a standard protocol. Similarly, it is acknowledged
that this study is biased toward TASC D lesions being
treated OPEN, likely as a result of the TASC I and II
recommendations. In addition, this studywas gathered from
data over a 20-year period during which patterns and trends
can change. Speciﬁc to this 20-year time period, ENDO
interventions became increasingly more favored for SFA and
popliteal disease for all ranges of clinical severity and
anatomic complexity. Personnel as well as experience with
both endovascular procedures and open surgery has
changed over time, and this is acknowledged as a weakness
of this paper. The high use of prosthetic conduit in the
OPEN group is likely also a function of the time period as
well as a majority of bypasses being above-the-knee.CONCLUSIONS
There has been a marked shift in treatment modality
for advanced femoro-popliteal disease with a lowering of
the symptomatic threshold for intervention over two
decades, likely spurred by the ease of endoluminal interven-
tions. Although peri-procedural and anatomic outcomes
for both procedures are equivalent, it appears that open
surgery carries a superior long-term clinical efﬁcacy. This
superiority is negatively inﬂuenced by poor preoperative
ambulation status, high modiﬁed Cardiac Risk Score, worse
presenting symptoms, the occurrence of MACE, poor
tibial runoff, the absence of hemodynamic success, and
occlusion of the original bypass.AUTHOR CONTRIBUTIONS
Conception and design: MD
Analysis and interpretation: MD, CS
Data collection: MD, CS, JA, YK, CB, MP, HE
Writing the article: MD, CS
Critical revision of the article: MD, CS
Final approval of the article: MD
Statistical analysis: MD, CS
Obtained funding: MD, AL
Overall responsibility: MDREFERENCES
1. Davies MG, Waldman DL, Pearson TA. Comprehensive endovascular
therapy for femoropopliteal arterial atherosclerotic occlusive disease.
J Am Coll Surg 2005;201:275-96.
2. Lumsden AB, Das TS. Endovascular management of infrainguinal
disease. J Endovasc Ther 2006;13(Suppl 2):II1-2.
3. Lumsden AB, Davies MG, Peden EK. Medical and endovascular
management of critical limb ischemia. J Endovasc Ther 2009;16(Suppl
II):II-31-62.
4. Lee LK, Kent KC. Infrainguinal occlusive disease: endovascular inter-
vention is the ﬁrst line therapy. Adv Surg 2008;42:193-204.
5. DeRubertis BG, Faries PL, McKinsey JF, Chaer RA, Pierce M,
Karwowski J, et al. Shifting paradigms in the treatment of lower
extremity vascular disease. A report of 1000 percutaneous interven-
tions. Ann Surg 2007;246:415-24.
6. Goodney PP, Beck AW, Nagle J, Welch HG, Zwolak RM. National
trends in lower extremity bypass surgery, endovascular interventions,
and major amputations. J Vasc Surg 2009;50:54-60.
7. Conte MS, Geraghty PJ, Bradbury AW, Hevelone ND, Lipsitz SR,
Moneta GL, et al. Suggested objective performance goals and clinical
trial design for evaluating catheter-based treatment of critical limb
ischemia. J Vasc Surg 2009;50:1462-73.
8. Goodney PP, Schanzer A, Demartino RR, Nolan BW, Hevelone ND,
Conte MS, et al; Vascular Study Group of New England. Validation of
the Society for Vascular Surgery’s objective performance goals for
critical limb ischemia in everyday vascular surgery practice. J Vasc Surg
2011;54:100-8.
9. Bakken AM, Palchik E, Hart JP, Rhodes JM, Saad WE, Davies MG.
Impact of diabetes on the outcomes of superﬁcial femoral artery
endoluminal interventions. J Vasc Surg 2007;46:946-58.
10. Smolock CJ, Anaya-Ayala JE, Bismuth J, Naoum JJ, El-Sayed HF,
Peden EK, et al. Impact of metabolic syndrome on the outcomes of
superﬁcial femoral artery interventions. J Vasc Surg 2012;55:985-93.
11. Smolock CJ, Anaya-Ayala JE, Bismuth J, Naoum JJ, El-Sayed HF,
Hassoun H, et al. Current outcomes for superﬁcial femoral artery
interventions: role of diabetes and renal insufﬁciency. JACC 2011;57.
E1580.
JOURNAL OF VASCULAR SURGERY
Volume 58, Number 5 Smolock et al 127512. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA,
Fowkes FG; TASC II Working Group. Inter-Society Consensus for the
Management of Peripheral Arterial Disease (TASC II). J Vasc Surg
2007;45(1 Suppl):S5-67.
13. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S,
et al. Recommended standards for reports dealing with lower extremity
ischemia: revised version. J Vasc Surg 1997;26:517-38.
14. Davies MG, Saad WE, Peden EK, Mohiuddin IT, Naoum JJ,
Lumsden AB. Impact of runoff on superﬁcial femoral artery endolu-
minal interventions for rest pain and tissue loss. J Vasc Surg 2008;48:
619-25.
15. Bakken AM, ProtackCD, SaadWEA, Rhodes JR,Hart JP,WaldmanDL,
et al. Impact of chronic kidney disease on outcomes of superﬁcial femoral
artery endoluminal interventions. Ann Vasc Surg 2009;23:560-8.
16. Smolock CJ, Anaya-Ayala JE, El-Sayed HF, Naoum JJ, Lumsden AB,
Davies MG. Clinical efﬁcacy of concomitant tibial interventionsassociated with superﬁcial femoral artery interventions in critical limb
ischemia. J Vasc Surg 2013;57:19-27.
17. Kashyap VS, Gilani R, Bena JF, Bannazadeh M, Sarac TP. Endovas-
cular therapy for acute limb ischemia. J Vasc Surg 2011;53:340-6.
18. Baril DT, Chaer RA, Rhee RY, Makaroun MS, Marone LK. Endo-
vascular interventions for TASC II D femoropopliteal lesions. J Vasc
Surg 2010;51:1406-12.
19. DeRubertis BG, Pierce M, Chaer RA, Rhee SJ, Benjeloun R, Ryer EJ,
et al. Lesion severity and treatment complexity are associated with
outcome after percutaneous infra-inguinal intervention. J Vasc Surg
2007;46:709-16.
Submitted Jul 17, 2012; accepted Feb 26, 2013.
Additional material for this article may be found online
at www.jvascsurg.org.DISCUSSIONMichael C. Stoner (Greenville, NC). Good morning
members and guests of the Society. Today, Dr Smolock and his
colleges from Houston have presented their two-decade experi-
ence with open and endovascular revascularization for complex
femoro-popliteal arterial occlusive disease. By the numbers, these
data are impressive, and represent over 2500 interventions for
severe claudication, rest pain, and tissue loss. The authors are to
be lauded for the 20-year study time frame, thus presenting us
with an evolving endovascular experience that mimics the national
transition to an endovascular-weighted stance towards lower
extremity arterial disease. In brief, the data, which likely represent
the practice pattern for many in this room, showed that patients
with systemic illness such diabetes or metabolic syndrome were
more likely to have percutaneous therapy, and bypass was more
commonly employed in TASC II D cases. While the surgeon-
centric outcome of primary assisted patency was similar in the
two groups, patient-centric outcomes involving limb salvage and
the novel “clinical efﬁcacy” favored patients undergoing bypass.
However, the data as presented are difﬁcult to draw meaningful
conclusions from. A few questions I have for the authors:
1. The most glaring issue, which was appropriately acknowl-
edged in the manuscript, is the selection bias. A large
well-sized longitudinal database such as this would most
appropriately be analyzed with a propensity score-weighted
proportional hazard model. Without such an analysis, these
data remain observational in nature, and the study fails to
reach its potential. Have you considered such an analysis
to correct for bias?
2. In your paper, there is a disconnect between assisted patency
and clinical efﬁcacy. This discordant ﬁnding highlights a major
issue in the vascular literature today. For instance, considerthe rather nebulous ﬁndings of theCLEVER trial. Do you think
that this discordance was related to the robustness or ABI
improvement following revascularization? It would be very
informative to stratify your clinical efﬁcacy endpoint by initial
ABI gain.
3. As your group gained experience with endovascular therapy,
did your selection criteria and outcomes change over time?
What about utilization of endovascular adjuncts such as stents
or atherectomy?
I’d like to speciﬁcally thank Dr Smolock for an advanced copy
of the manuscript, and the Society for the privilege of starting the
discussion.
Dr Christopher Smolock. Thank you for your questions,
Dr Stoner. We acknowledge selection bias, and we look forward
to conducting the analysis to correct for that bias in the paper.
The disconnect between the patencies and the clinical efﬁcacies
is something that has been very interesting to us, and I think it
does have to do with the patients being sicker in the endovas-
cular group: more diabetes, more metabolic syndrome, probably
worse small vessel disease even though tibial runoff scores were
better in the endovascular group. However, those runoff scores
only calculate to the ankle and do not include the foot arch or
angiosomes, thus not accounting for small vessel disease in
the foot. I believe this is probably tied together using the
ABI/TBI data. Endovascular therapy results in a lower ABI/
TBI than does open bypass. As the technology became avail-
able, the use of stents initially increased but then decreased
and leveled off as our group approach became fairly conservative
with minimal primary stenting, doing so for poor results or
dissection with angioplasty alone. We do not do very much
atherectomy.
Supplementary Table (online only). Patient variables
used for univariant and multivariant Cox proportional
hazard analysis
Patient factors Procedural factors Outcomes factors
Gender TASC II lesion
category
Hemodynamic success
Body mass
index >27
Recannulized Postprocedure symptom
outcome
Age >80 years Tibial runoff 30-day MACE
Smoking status Modiﬁed SVS
runoff score
30-day MALE
Coronary artery
disease
Complexity score 30-day amputation
Congestive heart
failure
Ambulation status
Modiﬁed cardiac
risk index
Postoperative discharge
status
Hypertension Postoperative ambulation
status
Coagulation defect Postoperative discharge
status
Cerebrovascular Occlusion of
intervention
Diabetes
Hypothyroidism
Hyperlipidemia
Statins
Metabolic syndrome
Hemodialysis
Creatinine >2
Pre-procedure
symptom
Preoperative
ambulation status
MACE, Major adverse cardiovascular event; MALE, major adverse limb
event; SVS, Society for Vascular Surgery; TASC II, TransAtlantic Inter-
Society Consensus II.
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Deﬁnitions used in the text of the paper.
Deﬁnitions: Coronary artery disease was deﬁned as
a history of angina pectoris, myocardial infarction, conges-
tive heart disease or prior coronary artery revascularizations.
The Modiﬁed Lee Index was used to quantify cardiac risk.1
Cerebrovascular disease was deﬁned as a history of stroke,
transient ischemic attack, or carotid artery revascularization.
Chronic renal impairment was deﬁned as an estimated glom-
ular ﬁltration rate <60 mL/min/1.73 m2 or if the patient
was on dialysis. Hypertension was deﬁned as a systolic blood
pressure>150 mmHg or diastolic blood pressure>90 mm
Hg on three occasions during a 6-month period. Hypercho-
lesterolemia was deﬁned as fasting serum concentrations of
cholesterol >200 mg/dL, a low-density lipoprotein >130
mg/dL, or triglycerides >200 mg/dL. Diabetes was
deﬁned as a fasting plasma glucose >110 mg/dL or an
HbA1c >7%. Noninsulin-dependent diabetes mellitus was
deﬁned as any patient with diabetes mellitus who did not
routinely receive insulin therapy for their diabetes manage-
ment. Insulin-dependent diabetes mellitus was deﬁned as
any patient with diabetes mellitus who routinely received
insulin therapy. Metabolic syndrome was deﬁned as previ-
ously described (insulin resistance or impaired glucose toler-
ance, hypertension, dyslipidemia, and abdominal obesity),2
with the exception of abdominal circumference, which was
not routinely recorded. We substituted a body mass index
score $30.0 as a positive score instead of an abdominal
circumference >102 cm or >88 cm for male or female
patients, respectively. Functional status was determined
preoperatively, at discharge, and again at 1 year postopera-
tively. Ambulation status was categorized as independently
ambulatory, ambulatory with assistance such as a cane or
a walker, wheelchair-bound, or bedridden. TASC II classiﬁ-
cation of disease severity for femoral lesions was used to
deﬁne the categories of lesions.3 The preoperative distal
runoff was scored by the number of patent tibial vessels
and according to a modiﬁcation of Society for Vascular
Surgery (SVS) criteria employed for determining bypass
runoff (using the cumulative score for the distal popliteal
from knee joint to ﬁrst tibial branch; maximum 9þ1) and
each of the tibial vessels (maximum 3 each), giving
a maximum possible total score of 19.4 The modiﬁed
PREVENT III amputation-free survival risk score allocated
points (pts) to each patient for the presence of dialysis (4 pts),
tissue loss (3 pts), age $75 (2 pts), and coronary artery
disease (1 pt).5 Total scores may then be used to stratify
each patient into low-risk (#3 pts), medium-risk (4-7 pts),
and high-risk ($8 pts) categories. In the FINNVasc Score
system,6 1 point was allocated for the presence of diabetes,
coronary artery disease, foot gangrene, and urgent opera-
tion, and the groups stratiﬁed into 5 categories
(0,1,2,3,4), with categories 3 and 4 being considered high
risk.
The SVS Objective performance goals (OPG) were
deﬁned at 30 days and 1 year.7 To satisfy the OPG, the
upper bound of the 95% conﬁdence interval (CI) mustbe # the OPG. Thirty-day OPG were major adverse limb
event rate (MALE; amputation or major reintervention
deﬁned as endovascular reintervention on the same leg,
placement of new bypass graft, use of thrombectomy or
thrombolysis, or major surgical revision such as a jump or
interposition graft), major adverse cardiovascular events
rate (MACE; myocardial infarction, stroke, or death) and
30-day above-ankle amputation rate. The 1-year OPG
used in this study were amputation-free survival: any
above-ankle amputation of the index limb or death (any
cause), perioperative death or any MALE. The SVS OPG
investigators designated patients with several important
characteristics to be “high-risk.” These high-risk groups
were designated as clinical high-risk (age over 80 and tissue
loss), anatomic high-risk (infrapopliteal distal target), and
conduit high-risk (absence of single-segment greater
saphenous vein greater than 3 mm in diameter).7 A death
within 30 days of the procedure was considered
procedure-related and a perioperative death. A major
complication was deﬁned as any event, regardless of how
minimal, not routinely observed after endoluminal therapy
that required treatment with a therapeutic intervention or
re-hospitalization within 30 days of the procedure.
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Volume 58, Number 5 Smolock et al 1275.e2Systemic complications were those related to cardiac,
pulmonary, renal, and sepsis. Local complications were
those related to access site, surgical wounds, and the
treated limb. Pre- and postprocedural symptoms were
deﬁned by SVS criteria,8 and a drop in symptom score of
1 or greater in follow-up was considered as recurrent symp-
toms. Primary, assisted primary, and secondary patency
rates were deﬁned in accordance with the reporting stan-
dards of the SVS.8 Clinical efﬁcacy was deﬁned as absence
of recurrent symptoms, maintenance of ambulation, and
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